Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Beijing Tiantan Biological Products Co., Ltd.
  6. News
  7. Summary
    600161   CNE000000WF9

BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.

(600161)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Beijing Tiantan Biological Products : Indonesia approves Sinopharm COVID-19 vaccine for emergency use

04/29/2021 | 11:22pm EDT

JAKARTA, April 30 (Reuters) - Indonesia's drug regulator on Friday approved a COVID-19 vaccine produced by China's Sinopharm, which is due to be used in a private vaccination scheme under which companies can buy government-procured vaccines to inoculate their staff.

No detailed efficacy data of Sinopharm's vaccine has been publicly released, but its developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), said the vaccine was 79.34% effective in preventing people from developing the disease, based on interim data. (Reporting by Agustinus Beo Da Costa and Stanley Widianto; Editing by Ed Davies)


ę Reuters 2021
All news about BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.
04/29BEIJING TIANTAN BIOLOGICAL PRODUCTSá : Indonesia approves Sinopharm COVID-19 vac..
RE
04/16EXCLUSIVE : Sinopharm to inject $4.6 billion vaccine assets into unit Tiantan Bi..
RE
04/16Sinopharm plans to inject $4.6 bln in assets into unit beijing tiantan biolog..
RE
More news
Financials
Sales 2021 3 928 M 608 M 608 M
Net income 2021 770 M 119 M 119 M
Net Debt 2021 - - -
P/E ratio 2021 59,0x
Yield 2021 0,42%
Capitalization 45 342 M 7 007 M 7 014 M
Capi. / Sales 2021 11,5x
Capi. / Sales 2022 9,89x
Nbr of Employees 3 592
Free-Float 45,3%
Chart BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Beijing Tiantan Biological Products Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 33,02 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
NameTitle
Dao Xing Fu General Manager & Director
Xiao Ming Yang Chairman
Hong Guang Wang Independent Director
Bo Tian Securities Representative
Xiang Ci Secretary
Sector and Competitors